Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugs
Sun Pharmaceutical is in focus.
· Economic Times Markets, ET Stocks
Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% tariffs on certain patented specialty pharmaceuticals and ingredients. Eligible products include rare-disease drugs, gene and cell therapies, and infertility treatments. Generic medicines remain outside the Section 232 tariffs.
The analysis
Sun Pharmaceutical reported movement of 100%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -1.8% on the day at ₹1,749.30, and has returned -7.2% over three months. It sits 13% below its 52-week high. The pharma & healthcare sector has moved +0.1% over the same period, so Sun Pharmaceutical is running 7.3 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- The company directly in focus is SUNPHARMA.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Taking Stock: Market fails to hold on to day#39;s gains, ends marginally higher
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price